Neurocrine Biosciences (NBIX) Price-to-Earnings (P/E) Ratio
Price: $107.69
Market Cap: $10.65B
Avg Volume: 1.58M
Market Cap: $10.65B
Avg Volume: 1.58M
Country: US
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Price-to-Earnings (P/E) Ratio Summary
Neurocrine Biosciences's P/E ratios across different time periods:
- TTM: 31.68
- Annual: 40.15
- Quarterly: 33.23
What is P/E Ratio?
The Price-to-Earnings (P/E) ratio is a valuation metric that compares a company's stock price to its earnings per share (EPS). It indicates how much investors are willing to pay for each dollar of company earnings.
Related Metrics
- Price-to-Book (P/B) Ratio: 5.29
- Price-to-Sales (P/S) Ratio: 5.82
Annual Ratios
Neurocrine Biosciences Historical P/E Ratio
Historical P/B Ratio
Historical P/S Ratio
TTM P/E Ratio
31.68
P/B Ratio (Annual)
5.29
P/S Ratio (Annual)
5.82
Neurocrine Biosciences Historical Valuation Metrics
The table below shows various valuation metrics for each year, with the latest data available for the last fiscal year 2024.
| Year | P/E Ratio | P/B Ratio | P/S Ratio |
|---|---|---|---|
| 2024 | 40.15 | 5.29 | 5.82 |
| 2023 | 51.55 | 5.77 | 6.82 |
| 2022 | 74.06 | 6.70 | 7.69 |
| 2021 | 89.92 | 5.86 | 7.11 |
| 2020 | 21.91 | 7.92 | 8.53 |
| 2019 | 266.19 | 15.46 | 12.50 |
| 2018 | 322.70 | 14.17 | 15.10 |
| 2017 | -47.90 | 18.35 | 42.24 |
| 2016 | -23.74 | 10.64 | 223.32 |
| 2015 | -53.75 | 11.26 | 241.79 |
| 2014 | -27.52 | 7.98 | 0.00 |
| 2013 | -13.54 | 5.18 | 213.73 |
| 2012 | 97.68 | 3.18 | 9.24 |
| 2011 | 12.48 | 7.81 | 6.06 |
| 2010 | -50.65 | 20.86 | 12.05 |
Related Metrics
Explore detailed financial metrics and analysis for NBIX.